Novel effects of On-Chung-Eum, the traditional plant medicine, on cytokine production in human mononuclear cells from Behçet's

Immunopharmacology and Immunotoxicology

Volumn 25, Issue 1, 2003, Pages 65-72

  Kim, Mi Sun ^a,b   Kim, Sung Oh ^a   Lim, Woon Ki ^b   Lee, Jeong Mi ^c   Hwang, Chung Yeon ^d   Cho, Kwang Ho ^e   Kim, Hyung Min ^a  

^a Wonkwang University   (South Korea)

^b Pusan National University   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Wonkwang University   (South Korea)

^e Wonkwang University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; ON CHUNG EUM; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD SAMPLING; CASE REPORT; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RELIABILITY; T LYMPHOCYTE ACTIVATION; TARGET CELL; TRADITIONAL MEDICINE;

ADULT; ANALYSIS OF VARIANCE; BEHCET SYNDROME; CASE-CONTROL STUDIES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON TYPE II; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PHYTOHEMAGGLUTININS; PHYTOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037232202     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-120018284     Document Type: Article

References (20)

1. Sakane, T.; Takeno, M.; Suzuki, N.; Inaba, G. Behçet's disease. N. Engl. J. Med. 1999, 341, 1284-1291.
2. Yazici, H.; Yurdakul, S.; Hamuryudan, V. Behçet's syndrome. Curr. Opin. Rheumatol. 1999, 11, 53-57.
3. Sayinalp, N.; Özcebe, O.I.; Özdemir, O.; Haznedaroǧlu, I.C.; Dündar, S.; Kirazli, Ş. Cytokines in Behçet's disease. J. Rheumatol. 1996, 23, 321-322.
4. Hamzaoui, K.; Hamza, M.; Ayed, K. Production of TNF-α and IL-1 active Behçet's disease. J. Rheumatol. 1990, 17, 1428-1429.
5. Yosipovitch, G.; Shohat, B.; Bshara, J.; Wysenbeek, A.; Weinberger, A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity. Isr. J. Med. Sci. 1995, 31, 345-348.
6. Fujii, N.; Minagawa, T.; Nakane, A.; Kato, F.; Ohno, S. Spontaneous production of gamma-interferon in cultures of T lymphocytes obtained from patients with Behçet's disease. J. Immunol. 1983, 130, 1683-1686.
7. Bacon, T.H.; Ozbakir, F.; Elms, C.A.; Denman, A.M. Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome. Clin. Exp. Immunol. 1984, 57, 541-547.
8. Kim, M.S.; Lim, W.K.; Cha, J.G.; An, N.H.; Yoo, S.J.; Park, J.H.; Kim, H.M.; Lee, Y.M. The activation of PI3-K and PKC ζ in PMA-induced differentiation of HL-60 cells. Cancer Lett. 2001, 171, 79-85.
9. Mayringer, I.; Reindl, M.; Berger, T. A critical comparison of frequently used methods for the analysis of tumor necrosis factor-α expression by human immune cells. J. Immunol. Methods 2000, 235, 33-40.
10. Sakane, T.; Takeno, M. Novel approaches to Behçet's disease. Exp. Opin. Investig. Drugs 2000, 9, 1993-2005.
11. Yamakawa, Y.; Sugita, Y.; Nagatani, T.; Takahashi, S.; Yamakawa, T.; Tanaka, S.I.; Nakamura, S.; Ohno, S.; Sekihara, H.; Okuda, K.; Nakajima, H. Interleukin-6 (IL-6) in patients with Behçet's disease. J. Dermatol. Sci. 1996, 11, 189-195.
12. al-Dalaan, A.; al-Sedairy, S.; al-Balaa, S.; al-Janadi, M.; Elramahi, K.; Bahabri, S.; Siddiqui, S. Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease. J. Rheumatol. 1995, 22, 904-907.
13. Ozoran, K.; Aydintug, O.; Tokgöz, G.; Düzgün, N.; Tutkak, H.; Gürler, A. Serum levels of interleukin-8 in patients with Behçet's disease. Ann. Rheum. Dis. 1995, 54, 610.
14. Katsantonis, J.; Adler, Y.; Orfanos, C.E.; Zouboulis, C.C. Adamentiades-Behçet's disease: serum IL-8 is more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000, 201, 37-39.
15. Bondeson, J.; Maini, R.N. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (Remicade). Int. J. Clin. Pract. 2001, 55, 211-216.
16. Tayor, P.C. Anti-tumor necrosis factor therapies. Curr. Opin. Rheumatol. 2001, 13, 164-169.
17. Hassard, P.V.; Binder, S.W.; Nelson, V.; Vasiliauskas, E.A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: case report. Gastroenterology 2001, 120, 995-999.
18. Zouboulis, C.C.; Orfanos, C.E. Treatment of Adamantiades-Behçet's disease with systemic interferon-α. Arch. Dermatol. Res. 1998, 134, 1010-1016.
19. Russell, A.I.; Lawson, W.A.; Haskard, D.O. Potential new therapeutic options in Behçet's syndrome. Biodrugs 2001, 15, 25-35.
20. Calabrese, L.; Fleischer, A.B. Thalidomide: current and potential clinical applications. Am. J. Med. 2000, 108, 487-495.